Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
PLACIDYL (ethchlorvynol) is an oral sedative-hypnotic capsule approved in 1961 for short-term treatment of insomnia. The mechanism of action involves central nervous system depression to induce sleep. This vintage small molecule represents a legacy product in the competitive sedative-hypnotic market.
LOE-approaching lifecycle suggests declining market presence and downsized commercial team; limited career growth opportunities on brand.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PLACIDYL offers limited career advancement opportunity given its LOE-approaching status and minimal linked job openings. This role is better suited for professionals specializing in legacy product management, regulatory maintenance, or operational efficiency in declining therapeutic areas.
Worked on PLACIDYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.